Cargando…
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial com...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482518/ https://www.ncbi.nlm.nih.gov/pubmed/31018870 http://dx.doi.org/10.1186/s40168-019-0679-5 |
_version_ | 1783413897823256576 |
---|---|
author | Hong, Bo-Young Sobue, Takanori Choquette, Linda Dupuy, Amanda K. Thompson, Angela Burleson, Joseph A. Salner, Andrew L. Schauer, Peter K. Joshi, Pujan Fox, Evan Shin, Dong-Guk Weinstock, George M. Strausbaugh, Linda D. Dongari-Bagtzoglou, Anna Peterson, Douglas E. Diaz, Patricia I. |
author_facet | Hong, Bo-Young Sobue, Takanori Choquette, Linda Dupuy, Amanda K. Thompson, Angela Burleson, Joseph A. Salner, Andrew L. Schauer, Peter K. Joshi, Pujan Fox, Evan Shin, Dong-Guk Weinstock, George M. Strausbaugh, Linda D. Dongari-Bagtzoglou, Anna Peterson, Douglas E. Diaz, Patricia I. |
author_sort | Hong, Bo-Young |
collection | PubMed |
description | BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues. RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity. CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40168-019-0679-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6482518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64825182019-05-02 Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis Hong, Bo-Young Sobue, Takanori Choquette, Linda Dupuy, Amanda K. Thompson, Angela Burleson, Joseph A. Salner, Andrew L. Schauer, Peter K. Joshi, Pujan Fox, Evan Shin, Dong-Guk Weinstock, George M. Strausbaugh, Linda D. Dongari-Bagtzoglou, Anna Peterson, Douglas E. Diaz, Patricia I. Microbiome Research BACKGROUND: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes, and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues. RESULTS: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity. CONCLUSIONS: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral mucositis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40168-019-0679-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-25 /pmc/articles/PMC6482518/ /pubmed/31018870 http://dx.doi.org/10.1186/s40168-019-0679-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hong, Bo-Young Sobue, Takanori Choquette, Linda Dupuy, Amanda K. Thompson, Angela Burleson, Joseph A. Salner, Andrew L. Schauer, Peter K. Joshi, Pujan Fox, Evan Shin, Dong-Guk Weinstock, George M. Strausbaugh, Linda D. Dongari-Bagtzoglou, Anna Peterson, Douglas E. Diaz, Patricia I. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
title | Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
title_full | Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
title_fullStr | Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
title_full_unstemmed | Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
title_short | Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
title_sort | chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482518/ https://www.ncbi.nlm.nih.gov/pubmed/31018870 http://dx.doi.org/10.1186/s40168-019-0679-5 |
work_keys_str_mv | AT hongboyoung chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT sobuetakanori chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT choquettelinda chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT dupuyamandak chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT thompsonangela chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT burlesonjosepha chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT salnerandrewl chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT schauerpeterk chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT joshipujan chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT foxevan chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT shindongguk chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT weinstockgeorgem chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT strausbaughlindad chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT dongaribagtzoglouanna chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT petersondouglase chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis AT diazpatriciai chemotherapyinducedoralmucositisisassociatedwithdetrimentalbacterialdysbiosis |